Table 2.
TA98 | TA100 | |
---|---|---|
M1 | 22.8 ± 5.7a | 27.1 ± 10.2ab |
M2 | 66.5 ± 5.1bc | 66.1 ± 5.6de |
M3 | 63.1 ± 10.1bc | 17.7 ± 8.5a |
M4 | 58.6 ± 10.7abc | 72.5 ± 7.3de |
M5 | 70.1 ± 3.6bc | 31.0 ± 10.7abc |
M6 | 66.5 ± 1.2bc | 42.8 ± 2.1abcd |
M7 | 41.1 ± 11.7ab | 30.9 ± 7.4abc |
M8 | 80.0 ± 7.0c | 63.7 ± 4.6cde |
M9 | 40.8 ± 11.7ab | 53.0 ± 9.3bcde |
M10 | 45.0 ± 11.4abc | 46.59 ± 6.9abcde |
M11 | 48.6 ± 9.6abc | 56.2 ± 11.6bcde |
M12 | 68.0 ± 5.5bc | 79.6 ± 4.3e |
M13 | 52.6 ± 11.4abc | 53.3 ± 2.9bcde |
M14 | 74.8 ± 7.4bc | 59.2 ± 7.2bcde |
M15 | 71.9 ± 4.8bc | 71.0 ± 7.1de |
Results are presented as the percentage of inhibition of AFB1 mutation and are representative of three repetitions.
Values with different letters within a column are significantly different (P < 0.05). Spontaneous revertants/plate were 31 ± 3 and 117 ± 6 and AFB1 control (500 ng) were 625 ± 26 and 958 ± 27 revertants/plate for TA98 and TA100, respectively.